213 related articles for article (PubMed ID: 23082308)
1. [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
Mateos JL; Wajchenberg BL
Drugs Today (Barc); 2012 Jul; 48 Suppl B():1-17. PubMed ID: 23082308
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
3. [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
MMW Fortschr Med; 2010 Oct; 152(40):44-5. PubMed ID: 21049644
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
5. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
6. The design of the liraglutide clinical trial programme.
Nauck MA
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():4-12. PubMed ID: 22405264
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
8. [Incretin-based therapy for treating patients with type 2 diabetes].
Jermendy G
Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
[TBL] [Abstract][Full Text] [Related]
9. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Niswender K; Pi-Sunyer X; Buse J; Jensen KH; Toft AD; Russell-Jones D; Zinman B
Diabetes Obes Metab; 2013 Jan; 15(1):42-54. PubMed ID: 22862847
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide for the treatment of type 2 diabetes: a clinical update.
Peters KR
Am J Ther; 2013; 20(2):178-88. PubMed ID: 21734532
[TBL] [Abstract][Full Text] [Related]
11. Potential of liraglutide in the treatment of patients with type 2 diabetes.
Deacon CF
Vasc Health Risk Manag; 2009; 5(1):199-211. PubMed ID: 19436648
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Pratley RE; Nauck MA; Bailey T; Montanya E; Filetti S; Garber AJ; Thomsen AB; Furber S; Davies M;
Diabetes Care; 2012 Oct; 35(10):1986-93. PubMed ID: 22851600
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Langer J; Hunt B; Valentine WJ
J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
[TBL] [Abstract][Full Text] [Related]
14. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Pratley R; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Garber A; Thomsen AB; Hartvig H; Davies M;
Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Fakhoury WK; Lereun C; Wright D
Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide: from clinical trials to clinical practice.
Gough SC
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
[TBL] [Abstract][Full Text] [Related]
18. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
20. [New concepts in the treatment of type 2 diabetes].
Meier JJ; Schmidt WE; Klein HH
Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
